Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents
- PMID: 18606952
- DOI: 10.1001/archpsyc.65.7.795
Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents
Abstract
Context: Selective serotonin reuptake inhibitors have been reported to increase the risk of upper gastrointestinal tract bleeding. The wide use of these drugs makes such potential risk a public health concern, and identification of factors that may increase or minimize such risk is necessary.
Objectives: To test the association of selective serotonin reuptake inhibitors and venlafaxine hydrochloride therapy with upper gastrointestinal tract bleeding, to identify subgroups of patients at particularly increased risk, and to explore whether acid-suppressing agents may be effective in minimizing risk.
Design: Nested case-control study.
Setting: General practice database from the United Kingdom.
Participants: One thousand three hundred twenty-one patients with upper gastrointestinal tract bleeding referred to a consultant or hospital and 10 000 control subjects matched for age, sex, and calendar year of the index date. Main Outcome Measure Risk of bleeding associated with selective serotonin reuptake inhibitors and effect of acid-suppressing agents.
Results: The percentage of current users of selective serotonin reuptake inhibitors (5.3%) or venlafaxine (1.1%) among case subjects was significantly higher than in matched control subjects (3.0% and 0.3%; adjusted odds ratio [OR], 1.6; 95% confidence interval [CI], 1.2-2.1, and OR, 2.9; 95% CI, 1.5-5.6, respectively). An interaction with nonsteroidal anti-inflammatory drugs (OR, 4.8; 95% CI, 2.8-8.3) was observed, in particular among those not using acid-suppressing agents (OR, 9.1; 95% CI, 4.8-17.3) compared with users of these drugs (OR, 1.3; 95% CI, 0.5-3.3). In addition, an interaction with antiplatelet drugs in nonusers of acid-suppressing agents was suggested (OR, 4.7; 95% CI, 2.6-8.3) compared with users of these drugs (OR, 0.8; 95% CI, 0.3-2.5).
Conclusions: Antidepressants with a relevant blockade action on the serotonin reuptake mechanism increase the risk of upper gastrointestinal tract bleeding. The increased risk may be of particular relevance when these drugs are associated with nonsteroidal anti-inflammatory drugs. Our study findings also provide evidence that use of acid-suppressing agents limits such increased risk.
Similar articles
-
Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.BMJ. 1999 Oct 23;319(7217):1106-9. doi: 10.1136/bmj.319.7217.1106. BMJ. 1999. PMID: 10531103 Free PMC article.
-
Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?Aliment Pharmacol Ther. 2005 Aug 1;22(3):175-81. doi: 10.1111/j.1365-2036.2005.02543.x. Aliment Pharmacol Ther. 2005. PMID: 16091054
-
Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding.Am J Gastroenterol. 2009 Jun;104(6):1475-82. doi: 10.1038/ajg.2009.128. Epub 2009 Apr 28. Am J Gastroenterol. 2009. PMID: 19491861
-
Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.Am J Gastroenterol. 2014 Jun;109(6):811-9. doi: 10.1038/ajg.2014.82. Epub 2014 Apr 29. Am J Gastroenterol. 2014. PMID: 24777151 Review.
-
Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding.Psychiatr Clin North Am. 2016 Sep;39(3):413-26. doi: 10.1016/j.psc.2016.04.010. Epub 2016 Jun 28. Psychiatr Clin North Am. 2016. PMID: 27514297 Review.
Cited by
-
Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.BMC Psychiatry. 2023 Nov 24;23(1):876. doi: 10.1186/s12888-023-05382-8. BMC Psychiatry. 2023. PMID: 38001423 Free PMC article.
-
Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management.World Psychiatry. 2023 Oct;22(3):366-387. doi: 10.1002/wps.21110. World Psychiatry. 2023. PMID: 37713568 Free PMC article.
-
Efficacy and safety of celecoxib for treatment of mild to moderate postpartum depression: a randomized, double-blind, placebo-controlled trial.Arch Gynecol Obstet. 2024 Apr;309(4):1429-1439. doi: 10.1007/s00404-023-07042-4. Epub 2023 Apr 25. Arch Gynecol Obstet. 2024. PMID: 37097311 Clinical Trial.
-
Melanin-like polydopamine nanoparticles mediating anti-inflammatory and rescuing synaptic loss for inflammatory depression therapy.J Nanobiotechnology. 2023 Feb 10;21(1):52. doi: 10.1186/s12951-023-01807-4. J Nanobiotechnology. 2023. PMID: 36765377 Free PMC article.
-
Risk for intracranial hemorrhage in individuals after mild traumatic brain injury who are taking serotonergic antidepressants.Front Neurol. 2022 Dec 7;13:952188. doi: 10.3389/fneur.2022.952188. eCollection 2022. Front Neurol. 2022. PMID: 36570453 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
